The role of the ErbB family in supporting the malignant phenotype was characterized by stable transfection of a single chain antibody (ScFv5R) against ErbB2 containing a KDEL endoplasmic reticulum retention sequence into GEO human colon carcinoma cells. The antibody traps ErbB2 in the endoplasmic reticulum, thereby down-regulating cell surface ErbB2. The transfected cells showed inactivation of ErbB2 tyrosine phosphorylation and reduced heterodimerization of ErbB2 and ErbB3. This resulted in greater sensitivity to apoptosis induced by growth deprivation and delayed tumorigenicity in vivo. Furthermore, decreased heterodimerization of ErbB2 and ErbB3 led to a reorganization in ErbB function in transfected cells as heterodimerization between epidermal growth factor receptor (EGFR) and ErbB3 increased, whereas ErbB3 activation remained almost the same. Importantly, elimination of ErbB2 signaling resulted in an increase in EGFR expression and activation in transfected cells. Increased EGFR activation contributed to the sustained cell survival in transfected cells.Protein-tyrosine kinases are involved in the regulation of cell growth and transformation. The binding of a ligand to the extracellular domain of a receptor tyrosine kinase induces receptor dimerization, activation of the intracellular kinase domain, and autophosphorylation (1). Tyrosine-phosphorylated residues serve as high affinity binding sites for Src homology 2-containing proteins and allow for the modulation of intracellular pathways (2, 3). Constitutive activation of these pathways is apparent in many malignancies and provides maintenance of the malignant phenotype as well as a viable target for cancer therapy.A number of receptor tyrosine kinase subclasses have been described, among which the ErbB family members are of particular interest because of their frequent involvement in human cancer (4, 5). Four members of this family are currently known: the epidermal growth factor (EGF) 1 receptor (EGFR/ ErbB1), ErbB2 (also called Neu/HER2), ErbB3, and ErbB4 (6). All of them share a similar primary structure, but they differ in their ligand specificity and kinase functions (7,8). Increased expression of EGFR is associated with relatively aggressive tumors of the stomach, bladder, lung, and breast (9). An abnormal level of EGFR has been correlated with tumor size and stage in head and neck cancer (10 -12). In this type of cancer, transforming growth factor-␣ and EGFR are both up-regulated (13). In patients with colon carcinoma, increased EGFR mRNA in the tumors is associated with a higher rate of liver metastasis (14). Previous work in this laboratory indicated that inappropriate expression of EGFR and its ligand, transforming growth factor-␣, associates with neoplastic transformation and induces malignant progression of human colon carcinoma (15, 16) as well as activation of ErbB2 (17).Receptor-receptor interactions between ErbB family members were first described by Stern and Kamps (18) and by Wada et al. (19) for EGFR and ErbB2. Ligand-induced receptor...